AcelRx Pharmaceuticals receives complete response letter from FDA for NDA
AcelRx announced the FDA has issued a Complete Response Letter for the Company's new drug application for Zalviso™ (sufentanil sublingual tablet system). The Company is currently reviewing the FDA's comments and requests contained in the CRL and plans to discuss these requests with the FDA. July 25, 2014